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Abstract 
This study describes the synthesis, antimicrobial activity, and in silico assessment of 1,2,4-oxadiazoles from ethyl levulinate. 
For that, we prepared arylamidoximes and treated them with ethyl levulinate, obtaining the respective 1,2,4-oxadiazoles through 
a reaction sequence of O-acylation followed by cyclodehydration. Then, we assessed the antimicrobial activity of these 
compounds against Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, and Candida 
utilis using the broth microdilution technique. We analyzed in silico studies using the online bioinformatics platforms 
SwissADME and PASS. We obtained arylamidoximes and 1,2,4-oxadiazoles in good yields. The 1,2,4-oxadiazoles showed 
moderate antimicrobial activity, inhibiting two microorganisms: the bacterium P. aeruginosa and the fungus C. utilis.  In silico 
studies of 1,2,4-oxadiazoles have shown promising properties, such as good oral absorption, low probability of toxicity, good 
body distribution, and potential to develop metabolic and enzymatic activities. The investigation of the antimicrobial activity 
together with the in silico studies showed that the synthesized 1,2,4-oxadiazoles are promising structures for the development 
of new therapeutic agents. 
Keywords: Antimicrobial activity, computational studies, heterocyclic, organic synthesis. 
 
Síntese, atividade antimicrobiana e estudo in silico de 1,2,4-oxadiazóis 
derivados do levulinato de etila 
 
Abstract 
Este estudo descreve a síntese, avaliação da atividade antimicrobiana e in silico de 1,2,4-oxadiazóis derivados do levulinato de 
etila. Nesse sentido, arilamidoximas foram preparadas e tratadas em seguida com o levulinato de etila, fornecendo os 
respectivos 1,2,4-oxadiazóis através de uma sequência reacional de O-acilação seguida de ciclodesidratação. A avaliação da 
ação antimicrobiana foi realizada contra Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Pseudomonas 
aeruginosa e Candida utilis através da técnica de microdiluição em caldo. Os estudos in sílico foram realizados através das 
plataformas digitais de bioinformática SwissADME e PASS online. As arilamidoximas e os 1,2,4-oxadiazóis foram obtidos em 
bons rendimentos. Os 1,2,4-oxadiazóis apresentaram atividade antimicrobiana moderada, uma vez que apresentaram inibição 
contra dois microrganismos, a bactéria P. aeruginosa e o fungo C. utilis. Os estudos in silico dos 1,2,4-oxadiazóis demonstraram 
propriedades promissoras, como boa absorção via oral, baixa probabilidade de apresentarem toxicidade, boa distribuição 
corpórea, bem como potencial de desenvolverem atividades metabólicas e enzimáticas. A investigação da ação antimicrobiana 
juntamente com os estudos in silico demostraram que os 1,2,4-oxadiazóis sintetizados são estruturas promissoras para o 
desenvolvimento de novos agentes terapêuticos. 
Palavras-chave: Ação antimicrobiana, estudos computacionais, heterocíclicos, síntese orgânica. 
 
 
Introduction 
Microbial resistance is a major public health problem 
worldwide, which is partly due to inappropriate and/or 
excessive use of antibiotic drugs (Prestinaci, Pezzotti, & 
Pantosti, 2015). Resistance occurs when microorganisms 
undergo genetic mutation through exposure to antimicrobial 
drugs, multiplying resistant organisms and thus hindering the 
treatment and cure of diseases (Prestinaci, Pezzotti & 
Pantosti, 2015). 
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A report published in 2019 by the US Centers for Disease 
Control and Prevention (CDC) estimates that more than 2.8 
million infections by antibiotic-resistant microorganisms occur 
annually in the USA, resulting in more than 35,000 deaths per 
year (CDC, 2019). In addition, a considerable portion of 
commercial antimicrobials (for example, posaconazole, 
ampicillin, ciprofloxacin) have limited action against resistant 
strains of microorganisms (Cunha, Nogueira, & Aguiar, 2018). 
These problems motivate the search for new sources of 
substances that may have antimicrobial action, stimulating 
investments aimed at promising compounds, such as those with 
the 1,2,4-oxadiazole ring in their structure. This heterocyclic 
nucleus has stood out for presenting several biological 
applications, acting as: antiasthmatic, antidiabetic, anti-
inflammatory, antitumor, neuroprotective, 
immunosuppressive, antioxidant, and antimicrobial (Freitas et 
al., 2012). Several studies highlight the promising 
antimicrobial activity of compounds containing the 1,2,4-
oxadiazole ring. Examples include the research by Krishna & 
collaborators (2015), Freitas & collaborators (2012), Cunha, 
Nougueira, & Aguiar (2018), Srivastava & collaborators 
(2003), and Leite & collaborators (2000). 
However, active compounds must undergo a rigorous 
process until their approval, which includes several obstacles 
and demands a lot of time and money. Moreover, many 
molecules do not reach the end of this process due to 
unfavorable physicochemical and/or biological characteristics 
that are only identified during the tests (Silva, 2016). 
Thus, to circumvent the obstacles in the development of a 
new drug, as well as to identify the most promising molecules 
in the early stages of this process, researchers have developed 
different in silico tools based on computational and 
mathematical methods. These methods have proven 
effectiveness in predicting a great diversity of biological and 
physicochemical characteristics of the compounds under study 
(Papa et al., 2017). 
Considering this and the countless reports of the 
antimicrobial action of 1,2,4-oxadiazole compounds, this study 
describes the synthesis, antimicrobial activity, and in silico 
assessment of 1,2,4-oxadizole compounds from ethyl 
levulinate. 
 
Materials and Methods 
 
Reagents and equipment 
Companies Vetec and Sigma-Aldrich provided the reagents 
and solvents with a degree of purity higher than or equal to 
98%. We purified the solvents - hexane and ethyl acetate - by 
fractional distillation in a Vigreux column. We monitored the 
reactions by thin layer chromatography (TLC) using silica gel 
plates containing fluorescent indicator F254, which we eluted in 
hexane/ethyl acetate systems and visualized using an 
ultraviolet lamp. 
We purified the resulting products by liquid column 
chromatography using Merck silica gel 60 (70-230 mesh) as 
the stationary phase and the solvents hexane and ethyl acetate, 
in different proportions, as the mobile phase. To evaporate the 
reaction solvent, we used a rotary evaporator (Büchi 
Rotavapor, model R-114) connected to a vacuum pump 
(KNF Neuberger). 
We characterized the structures of the compounds using 
hydrogen nuclear magnetic resonance (1H NMR) and carbon 
nuclear magnetic resonance (13C NMR) in a spectrometer 
(Varian Unity Plus), applying a frequency of 400 MHz for 
the hydrogen nucleus and 100 MHz for the carbon nucleus. 
For spectroscopic analyses, we used deuterated chloroform 
and dimethyl sulfoxide (CDCl3 and DMSO-d6) as solvents. 
We calibrated the device using Si(CH3)4 (0.0 ppm) as an 
external reference for 1H and 13C NMR. We expressed the 
chemical shifts in δ (ppm) and the coupling constants (J) in 
hertz (Hz). For the 1H NMR spectrum, we analyzed the shifts 
in relation to the central peak of CDCl3 at 7.27; for the 
13C 
NMR spectrum, we analyzed the shifts in relation to the 
central peak of CDCl3 at 77.0. 
 
Procedure for the synthesis of arylamidoximes (2a-c)  
We synthesized arylamidoximes (2a-c) by adapting the 
methodology of Andrade et al. (2016). For that, we added 
hydroxylamine hydrochloride (2.08 g; 30 mmol), sodium 
carbonate (1.6 g; 15 mmol), and 40 ml of distilled water at 
room temperature to a 125 ml round-bottom flask. Then we 
added 10.0 mmol of the corresponding nitrile (1a-c) 
dissolved in 40 ml of ethanol to the flask. We subjected the 
reaction mixture to an ultrasonic bath at 55 ± 5 °C for 30 
minutes, verifying the completion of the reaction by TLC. 
After completion, we evaporated the ethanol with the aid of 
a rotary evaporator for subsequent extraction of the organic 
phase. We extracted the organic phase from the aqueous 
medium using ethyl acetate (3 x 25 ml) with the aid of a 
separating funnel. After collection, we dried the organic 
phase with anhydrous Na2SO4. Then, we filtered and 
removed the extraction solvent under reduced pressure. We 
purified arylamidoximes (2a-c) by crystallization using the 
chloroform/hexane system (90:10). 
Benzamidoxime (2a): 1.09 g (80% yield); white solid: m.p. 
74-76 °C; IR (KBr pellet): max 3448, 3356, 3212, 3059, 
2893, 2361, 1645, 1590, 1499, 1446, 1384, 1107, 926, 768, 
687 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.63 (1H, s, 
OH), 7.69-7.67 (2H, m, HAromatic), 7.38-7.36 (3H, m, 
HAromatic), 5.81 (2H, s, NH2); 
13C NMR (100 MHz, DMSO-
d6) δ 150.8, 133.4, 128.9, 128.1, 125.4 (Tarasenko et al., 
2017). 
p-methylbenzamidoxime (2b): 1.35 g (90% yield); white 
solid: m.p. 144-146 ºC; IR (KBr pellet): max 3500, 3367, 
3049, 2916, 1664, 1588, 1418, 1391, 1099, 936, 823, 747 cm-
1; 1H NMR (400 MHz, DMSO-d6) δ 9.52 (1H, s, OH), 7.56 
(2H, d, J = 8.2 Hz, HAromatic), 7.17 (2H, d, J = 8.2 Hz, 
HAromatic), 5.73 (2H, s, NH2), 2.31 (3H, s, aryl-CH3); 
13C 
NMR (100 MHz, DMSO-d6) δ 150.8, 138.2, 130.5, 128.6, 
125.3, 20.8 (Andrade et al., 2016; Tarasenko et al., 2017).  
p-chlorobenzamidoxime (2c): 1.45 g (85% yield); white 
solid: m.p. 128-129 ºC; IR (KBr pellet): max 3468, 3346, 
3152, 3053, 2893, 2361, 1918, 1655, 1589, 1497, 1380, 
1087, 920, 840, 722 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
9.73 (1H, s, OH), 7.69 (2H, d, J = 8.6 Hz, HAromatic), 7.43 (2H, 
d, J = 8.6 Hz, HAromatic), 5.86 (2H, s, NH2); 
13C NMR (100 
MHz, DMSO-d6) δ 149.9, 133.4, 133.2, 128.1, 127.1 
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(Andrade et al., 2016; Tarasenko et al., 2017).  
Procedure for the synthesis of 4-(3-(aryl)-1,2,4-oxadiazol-5-
yl)-butan-2-one (4a-c) 
We synthesized 1,2,4-oxadiazoles (4a-c) following the 
methodology of Freitas & collaborators (2007) with some 
modifications. For that, we added ethyl 4-oxopentanoate 
(0.111 g, 0.75 mmol), the appropriate arylamidoximes (2a-c) 
(1.00 mmol), and K2CO3 (0.12 g, 0.85 mmol) to a small glass 
test tube. Then, we thoroughly ground this mixture. We 
subjected the glass test tube with the reaction mixture to 
irradiation in a domestic microwave oven (100% power, 650 
W) for 7 min, and then cooled it. Thereafter, we purified the 
crude product by chromatography on silica gel using 
hexane/ethyl acetate (9:1) to produce the corresponding 1,2,4-
oxadiazoles (4a-c). 
4-(3-(phenyl)-1,2,4-oxadiazol-5-yl)-butan-2-one (4a): 149.2 
mg (92% yield); colorless liquid; 1H NMR (400 MHz, CDCl3) 
 ppm 8.07-8.05 (m, 2H, HAromatic); 7.52-7.58 (m, 3H, HAromatic), 
3.22 (t, 2H, J = 7.2 Hz, HAlkylic); 3.09 (t, 2H, J = 7.2 Hz, HAlkylic); 
2.27 (s, 3H, HAlkylic), 
13C NMR (100 MHz, CDCl3)  205.2; 
178.7; 168.1; 131.0; 128.7; 127.3; 126.7; 39.2; 29.7; 20.6 
(Freitas et al., 2007). 
4-(3-(p-methylphenyl)-1,2,4-oxadiazol-5-yl)-butan-2-one 
(4b): 150.25 mg (87% yield); colorless liquid; 1H NMR (400 
MHz, CDCl3)  ppm 7.93 (d, 2H, J = 8.0 Hz, HAromatic); 7.28 (d, 
2H, J = 7.6 Hz, HAromatic); 3.20 (t, 2H, J = 6.8 Hz, HAlkylic); 3.07 
(t, 2H, J = 6.4 Hz, HAlkylic); 2.41 (s, 3H, HAlkylic); 2.26 (s, 3H, 
HAlkylic); 
13C NMR (100 MHz, CDCl3)  205.3; 178.6; 168.2; 
141.4; 129.4; 127.3; 123.9; 39.3; 29.8; 21.5; 20.7 (Freitas et 
al., 2007). 
4-(3-(p-chlorophenyl)-1,2,4-oxadiazol-5-yl)-butan-2-one (4c): 
169.21 mg (90% yield); colorless liquid; 1H NMR (400 MHz, 
CDCl3)  ppm 8.00 (d, 2H, J = 8.0 Hz, HAromatic); 7.46 (d, 2H, 
J = 8.8 Hz, HAromatic); 3.20 (t, 2H, J = 7.6 Hz, HAlkylic); 3.07 (t, 
2H, J = 6.4 Hz, HAlkylic); 2.26 (s, 3H, HAlkylic); 
13C NMR (100 
MHz, CDCl3)  205.1; 179.0; 167.4; 137.2; 129.1; 128.6; 
125.2; 39.1; 29.8; 20.6 (Freitas et al., 2007). 
In vitro assay of antimicrobial activity 
We assessed the in vitro antimicrobial activity of the 
synthesized 1,2,4-oxadiazoles (4a-c) against the bacteria 
Staphylococcus aureus (UFPEDA 02), Enterococcus faecalis 
(UFPEDA 138), Escherichia coli (UFPEDA 224), 
Pseudomonas aeruginosa (UFPEDA 416), and the fungus 
Candida utilis (UFPEDA 1009). We kept the microorganisms 
on nutrient agar (NA), stored at 4 °C. We used the 
antimicrobial drugs metronidazole and fluconazole as positive 
controls. We determined the values of the minimum inhibitory 
concentrations (MICs) according to the methodology of 
Espinel-Ingroff & collaborators (2005). 
 
Computational studies 
We obtained the values of consensual log Po/w (cLogP), 
molecular mass (MM), number of hydrogen bond donors 
(nHBD), number of hydrogen bond acceptors (nHBA), number 
of Lipinski rule violations, gastrointestinal absorption, blood-
brain barrier (BBB) permeation, and the presence of 
structural alert fragments through the SwissADME online 
bioinformatics platform. This platform compiles the 
contribution of different authors in the field of medicinal 
chemistry and chemoinformatics to process different in silico 
analyses (Daina, Michielin, & Zoete, 2017). 
We used the PASS online platform to survey the possible 
biological activities of compounds 4a-c, evaluating more 
than 3500 potential biological activities, including: 
pharmacological effects; mechanisms of action; toxic and 
adverse effects; interaction with metabolic enzymes and 
transporters; toxicological action for some organisms such as 
protozoa, microorganisms, and terrestrial and aquatic 
organisms that impact the environment; among other 
information (Oliveira, 2014). 
  
Results and Discussion 
This study initially considered a general strategy for the 
synthesis of 4-(3-(aryl)-1,2,4-oxadiazol-5-yl)-butan-2-ones 
(4a-c) (Figure 1). In this way, different arylnitriles (1a-c) 
reacted with hydroxylamine hydrochloride and basic salt in 
hydroethanolic medium under heating. The procedure led to 
the arylamidoximes (2a-c) with yields that ranged from 89-
92%, similarly to Freitas et al. (2007). The next step 
consisted of subjecting arylamidoximes (2a-c) and ethyl 4-
oxopentanoate (ethyl levulinate) to an O-acylation reaction 
followed by cyclodehydration, leading to compounds 4a-c. 
It is noteworthy that the synthesis of compounds 4a-c 
included microwave irradiation. The application of this form 
of heating proved to be very efficient since other procedures 
require high temperatures and generate byproducts, usually 
hindering purification (Freitas et al., 2012). 
The characterization of 1,2,4-oxadiazoles 4a-c by nuclear 
magnetic resonance of hydrogen (1H NMR) and carbon (13C 
NMR) led to spectroscopic data that corroborate literature 
values (Freitas et al., 2007). 
The growing need for new antimicrobial agents has been 
driven by several factors, mainly by the frequent cases of 
resistant microorganisms, encouraging the constant search 
for molecules that can help solve these problems (Lee & Lee, 
2018). Among the efforts in the search for new therapeutic 
agents, tests aimed at obtaining MIC values of compounds 
under development have stood out in the early stages of the 
process of discovering new drugs, providing highly reliable 
and safe results that help in the identification of promising 
compounds (Zorzi, 2013). Thus, the present study assessed 
the antimicrobial properties of compounds 4a-c with MIC 
values representing the lowest concentration capable of 
visually inhibiting 100% of the growth of the tested 
microorganism (Espinel-Ingroff et al., 2005). The study 
included microorganisms of clinical importance, which are 
frequently involved in infectious conditions and in 
antimicrobial resistance events. These microorganisms are 
the bacteria S. aureus (UFPEDA 02), E. faecalis (UFPEDA 
138), E. coli (UFPEDA 224), and P. aeruginosa (UFPEDA 
416), and the fungus C. utilis (UFPEDA 1009) (Table 1). 
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Figure 1. General strategy for the synthesis of 1,2,4-oxadiazoles 4a-c.  
 
All strains were susceptible to the antimicrobial activity of 
the standards used (metronidazole for bacterial strains and 
fluconazole for fungal strains), attesting to the feasibility of the 
tests. All compounds showed antimicrobial activity (Table 1). 
According to Morales & collaborators (2008), MIC values 
indicate good antimicrobial activity when in the range of 50-
500 μg mL-1, moderate activity when in the range of 500-1500 
μg mL-1, and poor activity when above 1500 μg mL-1. Thus, 
the antimicrobial activities of compounds 4b and 4c proved to 
be poor or close to the maximum limit of the moderate range 
for the strains. Meanwhile, compound 4a had moderate 
antimicrobial activity, with MIC values of 625 μg mL-1 for P. 
aeruginosa and 156.2 μg mL-1 for C. utilis. 
 
Table 1. Antimicrobial activity of the compounds 4a-c and the 
positive controls (metronidazole and fluconazole), represented 
by the minimum inhibitory concentration (MIC) in μg mL-1. 
Compound 
S. 
aureus 
E. 
faecalis 
E. 
coli 
P. 
aeruginosa 
C. 
Utilis 
4a + + + 625 156.2 
4b + + + + 2500  
4c + + + 2500 1250  
Metronidazole 19.5 19.5 19.5 19.5 - 
Fluconazole - - - - 19.5 
(+) denotes bacterial growth; (-) not evaluated 
 
Srivastava & collaborators (2003) studied 1,2,4-oxadiazole 
compounds with molecular architecture similar to that of the 
compounds of the present study, observing moderate 
antimicrobial activity. However, these authors synthesized a 
compound with greater similarity to compound 4a, which does 
not contain a substituent in the aryl group, not showing any 
antimicrobial action against the microorganisms of their 
experiment. Leite & collaborators (2000) also studied 
antimicrobial activity using compounds similar to those of the 
present study and obtained satisfactory results, with MICs of 
64 μg mL-1 and 128 μg mL-1 against E. coli and Proteus 
mirabilis, respectively. In that study, the compounds also acted 
against P. aeruginosa, however, with little effect. 
Considering the low antifungal activity of 1,2,4-oxadiazole 
compounds with similar structure (Krishna & collaborators, 
2015), the antifungal activity of compound 4a in the present 
study is an extremely relevant result. 
The antimicrobial evaluation of compounds 4a-c showed 
the electronic influence of the substituents introduced in the 
aromatic ring. For example, the compound containing the 
leaving group (-Cl) showed a lower MIC in relation to the 
compound containing the donor group (-CH3). 
Aiming to know the theoretical pharmacokinetic, 
toxicological, and chemical characteristics of compounds 4a-
c, the next step of the present research consisted of the 
computational study of these compounds using the 
SwissADME platform (Table 2). 
 
Table 2. In silico pharmacokinetic, toxicological, and 
chemical properties of compounds 4a-c. 
Property 
Compound 
4a 4b 4c 
cLogP 2.12 2.51 2.64 
MM 216.24 230.26 250.68 
nHBD 0 0 0 
nHBA 4 4 4 
Lipinski 0 0 0 
GI Absorption High High High 
BBB Yes Yes Yes 
Alert fragments No No No 
cLogP: consensual Log Po/w; MM: molecular mass; nHBD: number 
of hydrogen bond donors; nHBA: number of hydrogen bond 
acceptors; Lipinski: number of Lipinski rule violations; GI 
Absorption: gastrointestinal absorption; BBB: blood-brain barrier. 
 
The cLogP value corresponds to the lipophilicity of 
compounds 4a-c (Table 2). Before the drug interacts with its 
pharmacological target, it must be able to penetrate through 
body barriers and reach its place of action, a process driven 
by its pharmacokinetic characteristics. According to Barreiro 
& Fraga (2015), the ability of drugs to permeate through 
body barriers and distribute themselves throughout the body 
relate directly to the lipophilicity of the compound. These 
authors consider LogP values between 1 and 3 as the ideal 
lipophilicity range for a drug. Thus, compounds 4a-c showed 
cLogP values within the ideal lipophilicity range, which 
points to good pharmacokinetic characteristics. 
In this sense, the evaluation of compounds 4a-c followed 
the Lipinski ‘Rule of Five’ (2004). Lipinski developed this 
rule from the analysis of 2,245 drugs that showed good 
standards of oral bioavailability, making it one of the main 
starting points in the development of new promising 
molecules. The study determines that a molecule will present 
a good standard of oral bioavailability when it satisfies a set 
of physicochemical parameters, which are: molecular mass 
(MM) less than 500 Daltons, partition coefficient (cLogP) 
less than 5, maximum of five hydrogen bond donor groups 
(nHBD), and maximum of ten hydrogen bond acceptor 
groups (nHBA) (Lipinski, 2004). All the compounds of the 
present study satisfy all the specifications contained in the 
‘Rule of Five’ (Table 2), corroborating the good 
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pharmacokinetic potential presented by the cLogP analysis. 
This points to the high potential of these compounds to be well 
absorbed after oral administration, which is a relevant fact. 
This type of administration has unique benefits such as 
convenience, low cost, possibility of self-administration, 
greater adherence to treatment, and lower risk of triggering 
systemic infections in the user (Golan et al., 2014). 
Additionally, the high gastrointestinal (GI) absorption and 
the ability to cross the blood-brain barrier (BBB), both 
indicated by the SwissADME platform, are further evidence of 
the good pharmacokinetic characteristics of these compounds. 
The estimate of high gastrointestinal absorption reinforces the 
results of the other analyses, while the ability to cross the BBB 
indicates good patterns of body distribution, showing the 
ability of these compounds to access the central nervous 
system and fight diseases therein (Table 2) (Daina, Michielin, 
& Zoete, 2017). 
Compounds 4a-c do not have alert fragments in their 
molecular structure, indicating a good toxicity pattern (Table 
2). This analysis was performed by the SwissADME platform 
following Brenk & collaborators (2008), who created a list of 
molecular fragments known to be toxic, chemically reactive, 
metabolically unstable, or to be responsible for unsatisfactory 
pharmacokinetic standards. 
Together, the results of lipophilicity, oral bioavailability, 
and toxicity highlight these molecules as good candidates for 
the development of new therapeutic agents. It is noteworthy 
that 80% of the molecules under research do not reach clinical 
studies, and 50% of them are unsuccessful due to unfavorable 
pharmacokinetic and toxicological properties (Silva, 2016). 
Continuing the in silico studies, the present research 
included the analysis of compounds 4a-c on the online platform 
PASS, which addresses more than 3500 potential biological 
activities expressed as probability “to be active” (Pa) (Oliveira, 
2014). The main activities reported by the platform for these 
compounds were their effects on different physiological agents 
such as enzymes and receptors. These reports highlight their 
inhibitory activity on the tyrosine kinase platelet-derived 
growth factor receptor (PDGFR), a receptor identified as a 
possible target in cancer treatment. For this receptor, the Pa 
values ranged from 82.3% to 85.3%. 
Compounds 4a-c also showed other important activities, of 
which stand out the anti-inflammatory (Pa values ranging from 
60.3% to 62.8%), antiprotozoal (Pa values ranging from 42.3% 
to 50.2%), and anxiolytic (Pa values varying from 40.0% to 
47.2%). 
The results corroborate different scientific studies for other 
oxadiazole compounds. Ranjan & collaborators (2018) 
explored the anti-inflammatory activity of 1,2,4-oxadiazoles, 
pointing out compounds more active and selective than the 
standard drug, ketoprofen. Chaves & collaborators (2017) 
reported the action of different oxadiazoles against different 
species of the genus Leishmania spp., with IC50 values below 
11 µM for promastigote forms and below 5 µM for amastigote 
forms. Faizi & collaborators (2012) demonstrated the 
anxiolytic activity of oxadiazoles, suggesting activity on 
GABA receptors similar to that of drugs used for this purpose, 
such as benzodiazepines. 
These results show how promising these compounds are, 
with the possibility of becoming good drugs in the future. 
The present research corresponds to the first steps in the 
process of discovering new drugs and encouraging the 
development of future studies on these molecules and their 
derivatives. 
 
Conclusion 
In summary, the present study synthesized three 
compounds containing the 1,2,4-oxadiazole nucleus from 
ethyl levulinate, in yields ranging between 87-92%. The in 
vitro evaluation of the synthesized compounds against 
different bacterial strains and a fungal strain demonstrated 
promising antimicrobial activity. The compounds inhibited 
the bacterium P. aeruginosa and the fungus C. utilis with 
moderate to high minimum inhibitory concentration (MIC) 
values. In addition, computational studies have shown 
promising properties for the three 4-(3-(aryl)-1,2,4-
oxadiazol-5-yl)-butan-2-ones, indicating the possibility of 
these molecules being well absorbed after oral 
administration, with low probability of toxicity and good 
body distribution. Moreover, these compounds showed good 
metabolic and enzymatic activities, also acting as anti-
inflammatory, antiprotozoal, and anxiolytic agents. 
The prospecting of new bioactive molecules has stood 
out as one of the main initiatives to supply the need for new 
drugs, mainly antimicrobials. The present research points to 
the need for developing future studies that can help enhance 
the demonstrated antimicrobial activity of these compounds. 
Further research should also evaluate other possible 
activities of these molecules and their derivatives, thus 
contributing to the implementation of new therapeutic 
agents. 
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